ABX464 safe, effective in treating patients with ulcerative colitis


Sumary of ABX464 safe, effective in treating patients with ulcerative colitis:

  • Abivax announced positive phase 2b clinical induction and results for ABX464 in the treatment of patients with moderate to severe ulcerative colitis, according to a press release..
  • Further, compared with placebo, patients dosed with ABX464 demonstrated endoscopic improvement, clinical remission, clinical response and reduction of fecal calprotectin..
  • Researchers observed further increased and durable clinical remission and endoscopic improvement in 51 patients treated with ABX464 50 mg after 48 weeks of open-label maintenance..
  • “The phase 2b results demonstrate the potential of ABX464 to become a gamechanger for the treatment of UC patients in need of new therapeutic management options..
  • “Based on these data, we are now moving forward as quickly as possible with our phase 3 plan in ulcerative colitis as well as phase 2b/3 in Crohn disease to bring ABX464 to the many patients suffering from inflammatory bowel disease.”…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.